Skip to news
JQJO
Latest

Menopause Treatment: New Hope, Cautious FDA | JQJO

Menopause Treatment: New Hope, Cautious FDA

Menopause Treatment: New Hope, Cautious FDA

Tap title to read story

0:00 / 0:37

Isabel Kallman, 53, experiences perimenopause symptoms and considers hormone therapy (HT). Concerns about HT's risks, stemming from a flawed 2002 study, have lingered. However, recent research suggests that age at treatment start and dosage significantly impact safety. Doctors now emphasize individualized risk assessment and tailored treatment plans, often involving low-dose options. While the FDA considers altering HT warnings, some experts urge caution, demanding more data before label changes.

Published · Published by JQJO

Published by JQJO Editorial Desk · AI assisted

More context

Sources

JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.

Editorial policy and corrections · Our team

Lakers Edge Kings 106-104

Tap title to read story

0:00 / 0:40

Oregon Rout Michigan State 45‑7

Tap title to read story

0:00 / 0:40

Chiefs Add Josh Downs, Seek More

Tap title to read story

0:00 / 0:00

Oregon Ducks Lose Hill to Injury

Tap title to read story

0:00 / 0:35

Clemson QBs Beat Duke 20-10

Tap title to read story

0:00 / 0:42

JQJO

Find your next story

Search JQJO’s current coverage.